TransMedics Group (NASDAQ:TMDX) Stock Price Up 2%

Shares of TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) were up 2% during mid-day trading on Wednesday . The stock traded as high as $95.62 and last traded at $95.13. Approximately 417,047 shares traded hands during trading, a decline of 37% from the average daily volume of 667,192 shares. The stock had previously closed at $93.24.

Analyst Ratings Changes

TMDX has been the topic of several research reports. JPMorgan Chase & Co. upped their target price on TransMedics Group from $87.00 to $105.00 and gave the company an "overweight" rating in a research report on Tuesday, February 27th. Piper Sandler initiated coverage on TransMedics Group in a report on Thursday, March 28th. They issued an "overweight" rating and a $95.00 price objective on the stock. Oppenheimer lifted their target price on TransMedics Group from $92.00 to $105.00 and gave the stock an "outperform" rating in a report on Tuesday, February 27th. Finally, Morgan Stanley boosted their target price on shares of TransMedics Group from $75.00 to $95.00 and gave the company an "equal weight" rating in a research report on Wednesday, February 28th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $102.00.

TransMedics Group Stock Performance

The company has a debt-to-equity ratio of 3.69, a current ratio of 9.30 and a quick ratio of 8.49. The stock has a market cap of $3.13 billion, a P/E ratio of -124.22 and a beta of 1.99. The stock has a 50-day simple moving average of $82.40 and a 200-day simple moving average of $71.43.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings results on Monday, February 26th. The company reported $0.12 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.22. The company had revenue of $81.20 million for the quarter, compared to analyst estimates of $68.49 million. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The firm's revenue was up 158.6% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.21) EPS. Research analysts forecast that TransMedics Group, Inc. will post -0.14 earnings per share for the current year.

Insider Activity

In other news, insider Tamer I. Khayal sold 10,000 shares of the business's stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $80.41, for a total transaction of $804,100.00. Following the sale, the insider now directly owns 14,375 shares in the company, valued at $1,155,893.75. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, insider Tamer I. Khayal sold 15,512 shares of the firm's stock in a transaction on Tuesday, April 9th. The stock was sold at an average price of $90.45, for a total transaction of $1,403,060.40. Following the completion of the transaction, the insider now directly owns 25,185 shares of the company's stock, valued at approximately $2,277,983.25. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, insider Tamer I. Khayal sold 10,000 shares of TransMedics Group stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $80.41, for a total value of $804,100.00. Following the transaction, the insider now directly owns 14,375 shares in the company, valued at $1,155,893.75. The disclosure for this sale can be found here. In the last ninety days, insiders sold 113,408 shares of company stock worth $9,465,421. Insiders own 6.70% of the company's stock.

Hedge Funds Weigh In On TransMedics Group

A number of hedge funds have recently made changes to their positions in the stock. FMR LLC raised its holdings in TransMedics Group by 42.5% during the 3rd quarter. FMR LLC now owns 4,714,870 shares of the company's stock worth $258,139,000 after purchasing an additional 1,407,171 shares during the last quarter. Eventide Asset Management LLC lifted its holdings in TransMedics Group by 1,271.7% in the third quarter. Eventide Asset Management LLC now owns 925,356 shares of the company's stock valued at $50,663,000 after buying an additional 857,895 shares during the period. Mackenzie Financial Corp bought a new stake in TransMedics Group during the fourth quarter valued at $35,804,000. Summit Partners Public Asset Management LLC grew its holdings in TransMedics Group by 71.9% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 957,282 shares of the company's stock worth $59,083,000 after acquiring an additional 400,255 shares during the period. Finally, Bank of New York Mellon Corp raised its position in shares of TransMedics Group by 91.4% in the 3rd quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company's stock worth $41,615,000 after acquiring an additional 363,012 shares in the last quarter. 99.67% of the stock is currently owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.